<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id><journal-id journal-id-type="publisher-id">abc</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27411096</article-id><article-id pub-id-type="pmc">5074068</article-id><article-id pub-id-type="doi">10.5935/abc.20160100</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group><subject>Ischemia/Myocardial Infarction</subject></subj-group></subj-group></article-categories><title-group><article-title>Is Local Nitric Oxide Availability Responsible for Myocardial Salvage
after Remote Preconditioning?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Arroyo-Mart&#x000ed;nez</surname><given-names>Esbeidira Aranet</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Meaney</surname><given-names>Alejandra</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Guti&#x000e9;rrez-Salme&#x000e1;n</surname><given-names>Gabriela</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rivera-Capello</surname><given-names>Juan Miguel</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gonz&#x000e1;lez-Coronado</surname><given-names>Vidal</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Alcocer-Chauvet</surname><given-names>Alejandro</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Castillo</surname><given-names>Genaro</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>N&#x000e1;jera</surname><given-names>Nayelli</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ceballos</surname><given-names>Guillermo</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="fn1">*</xref></contrib><contrib contrib-type="author"><name><surname>Meaney</surname><given-names>Eduardo</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="fn1">*</xref><xref ref-type="corresp" rid="c1"/></contrib></contrib-group><aff id="aff1"><label>1</label>Unidade Cardiovascular - Hospital "Primero de Octubre", Cidade do
M&#x000e9;xico - M&#x000e9;xico</aff><aff id="aff2"><label>2</label>Faculdade de Ci&#x000ea;ncias da Sa&#x000fa;de, Universidade
An&#x000e1;huac M&#x000e9;xico Norte, Cidade do M&#x000e9;xico - M&#x000e9;xico</aff><aff id="aff3"><label>3</label>Laborat&#x000f3;rio de Investiga&#x000e7;&#x000e3;o Integral
Cardiometab&#x000f3;lica. Se&#x000e7;&#x000e3;o de Estudos de
P&#x000f3;s-gradua&#x000e7;&#x000e3;o e Investiga&#x000e7;&#x000e3;o. Escola Superior de
Medicina, Instituto Polit&#x000e9;cnico Nacional, Cidade do M&#x000e9;xico -
M&#x000e9;xico</aff><author-notes><corresp id="c1"><bold>Mailing Address: Eduardo Meaney</bold>, Laboratorio de
Investigaci&#x000f3;n Integral Cardiometab&#x000f3;lica. Secci&#x000f3;n de
Estudios de Posgrado e Investigaci&#x000f3;n. Escuela Superior de Medicina,
Instituto Polit&#x000e9;cnico Nacional. Plan de San Luis y D&#x000ed;az
Mir&#x000f3;n s/n. Col. Casco de Santo Tom&#x000e1;s. Del. Miguel Hidalgo. Postal
Code: 11340. M&#x000e9;xico, DF - M&#x000e9;xico. E-mail:
<email>lalitomini@prodigy.net.mx</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>8</month><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>8</month><year>2016</year></pub-date><volume>107</volume><issue>2</issue><fpage>154</fpage><lpage>162</lpage><history><date date-type="received"><day>22</day><month>10</month><year>2015</year></date><date date-type="rev-recd"><day>12</day><month>11</month><year>2015</year></date><date date-type="accepted"><day>6</day><month>5</month><year>2016</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Background:</title><p>Remote ischemic preconditioning (RIPC) represents an attractive therapy for
myocardial protection, particularly when ischemic events can be anticipated.
Although several hypothetic mechanisms have been proposed, no definite
molecular pathways have been elucidated.</p></sec><sec><title>Objective:</title><p>We evaluated the effect of brachial circulation cuff occlusion on myocardial
ischemic tolerance, necrosis, and nitric oxide (NO) in patients with
ischemic heart disease undergoing elective percutaneous coronary
interventions (PCI).</p></sec><sec><title>Methods:</title><p>46 patients were randomly allocated into two groups: control and RIPC before
PCI procedures. Electrocardiographic analysis, serum concentrations of
troponin I (cTn-I) were measured at baseline and 24 hours after PCI. A blood
sample from the atherosclerotic plaque was drawn to determine nitrate and
nitrites.</p></sec><sec><title>Results:</title><p>RIPC increased the availability of NO in the stented coronary artery. Control
patients presented a small but significant increase in cTn-I, whilst it
remained unchanged in preconditioned group. The preconditioning maneuver not
only preserved but also enhanced the sum of R waves.</p></sec><sec><title>Conclusions:</title><p>RIPC induced an intracoronary increase of NO levels associated with a
decrease in myocardial damage (measured as no increase in cTn-I) with
electrocardiographic increases in the sum of R waves, suggesting an improved
myocardium after elective PCI.</p></sec></abstract><kwd-group><kwd>Nitric Oxide</kwd><kwd>Ischemia</kwd><kwd>Ischemic Preconditioning, Myocardial</kwd><kwd>Reperfusion</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Ischemic preconditioning is a well-known phenomenon by which short periods of
ischemia-reperfusion provide an increased tolerance to subsequent sustained ischemic
episodes.<sup><xref rid="r1" ref-type="bibr">1</xref></sup> Remote ischemic
preconditioning (RIPC), i.e., the increased myocardial tolerance to ischemic insults
after short-term ischemia-reperfusion episodes induced in a distant body tissue or
organ, has demonstrated a conspicuous capacity against ischemia, stunning, as well
as an ability to limit infarct size in both animal models and humans.<sup><xref rid="r2" ref-type="bibr">2</xref>-<xref rid="r5" ref-type="bibr">5</xref></sup></p><p>Although the specific underlying molecular pathways are yet poorly understood, there
is a handful of hypothetic mechanisms explaining this rather intriguing phenomenon.
Neural [e.g., bradykinin and nitric oxide (NO)], humoral (e.g., adenosine and
angiotensin), and systemic protective response (i.e., suppressing inflammation and
apoptosis) premises, acting either alone or intertwined, have been proposed as
possible mechanistic processes of RIPC.<sup><xref rid="r6" ref-type="bibr">6</xref></sup> The pragmatic implementation of techniques of remote
preconditioning uncovers a promising therapeutic field for myocardial salvage and
protection, particularly when ischemic events can be anticipated, as in percutaneous
coronary interventions (PCI) or aorto-coronary bypass graft surgery, among
others.</p><p>Interestingly, it has been proposed that NO may play a relevant and perhaps decisive
role resulting in myocardial protection. However, to our best knowledge, a direct
measure of NO in the coronary territory, after periphery conditioning and just
before reperfusion, has not been assessed.</p><p>The purpose of this study was to evaluate the effect of brachial circulation cuff
occlusion on myocardial ischemic tolerance, myocardial necrosis, NO bioavailability
at the site of angioplasty and renal function in patients with ischemic heart
disease undergoing elective PCI.</p></sec><sec sec-type="methods"><title>Methods</title><p>Based on the study by Hoole,<sup><xref rid="r7" ref-type="bibr">7</xref></sup> in
which serum cardiac troponin I (cTn) was increased more than 30% in control patients
compared with those who underwent a RIPC 24 hours after elective PCI, a sample size
of 14 patients was estimated to provide 80% power and 95% of confidence.
Anticipating a 20% of losses, and 15% reduction of elevated cTn-I, a group of 46
patients (23 in each of the control and RIPC intervention groups) was assembled.</p><p>Study protocol was approved by both Ethics and Research Institutional Committees and
it was conducted according to the Declaration of Helsinki, Good Clinical Practices
and Mexican Federal Regulations.<sup><xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r9" ref-type="bibr">9</xref></sup> We included patients of any gender,
aged &#x02265;18 years, who signed an informed consent, had documented clinical
evidence of ischemic heart disease, accepted PCI therapeutic procedures and had
concentrations of serum cTn-I less than three times de 99<sup>th</sup> percentile
value. Exclusion criteria include: patients with acute coronary syndromes or
hemodynamic instability, those requiring immediate angioplasty and stenting
procedures, pregnant or breastfeeding women, and those patients medicated with drugs
having effects as activators of potassium channels, as glibenclamide or
nicorandil.</p><p>All patients were medicated with aspirin (300 mg) and clopidogrel (600 mg) the day
before the PCI. All selected patients concluded the trial.</p><p>One hour before the PCI procedure, a 12-lead electrocardiogram (ECG) was obtained.
Then the ECG was repeated 24 hours after PCI. Electrocardiographic analysis
comprehended the quantitation of the positive or negative ST deviation, new Q waves,
and the occurrence of sudden left bundle branch block (LBBB). The summation of R
waves (&#x003a3;R), in mm, was carried out in precordial leads and in all 12
leads.</p><p>Additionally, a peripheral venous blood sample was drawn to measure serum
concentrations of troponin-I by means of monoclonal antibody-immunoassay with a
Bayer ADVIA 60 hematology analyzer, whose 99<sup>th</sup> percentile value is 0.04
ng/mL. The variation coefficient of the assay is less than 10%<sup><xref rid="r10" ref-type="bibr">10</xref></sup> in our laboratory. Troponin-I was
measured at baseline and 24 hours after PCI.</p><p>After recruitment, patients were randomly allocated in two groups, one serving as
controls and another in which patients underwent ischemic preconditioning. In these
latter subjects, 1 hour before the PCI procedure a RIPC maneuver was carried out
with patients lying in dorsal decubitus. RIPC was done in the left arm, using three
cycles of cuff occlusion, raising the pressure to 200 mm Hg during a period of 5
minutes followed by a 5-minute period of cuff deflation. Afterwards, all patients
underwent a standard PCI procedure, including the stenting of all susceptible and
accessible coronary lesions. The different interventional cardiologists involved in
the study were blinded to the preconditioning maneuver. Before stenting, the tip of
the catheter was placed just in the site of the atherosclerotic plaque to be
stented, and a blood sample was drawn to measure nitrate and nitrites (NOx), the
degradation products of NO, as an indirect measure of disposability of this gas,
which in turn is an emblematic marker of endothelial function. NO metabolites
concentrations were measured using a commercially available colorimetric enzymatic
Kit (Cayman, Chemicals), following manufacturer's instructions. Optical density was
determined at 540 nm. Since NOx is excreted through the kidney, the ratio
NOx/creatinine was estimated in order to rule out the influence of any renal
impairment.</p><p>Angina pain experienced during PCI was quantified with a modified scale of the
American College of Sports Medicine<sup><xref rid="r11" ref-type="bibr">11</xref></sup> in grade 0 (no pain or discomfort at all), grade 1 (light,
barely noticeable), grade 2 (moderate, bothersome), grade 3 (severe, very
uncomfortable) and grade 4 (most severe pain never experienced).</p><p><underline>Periprocedural myonecrosis/myocardial infarction</underline>. Myocardial
necrosis was considered when serum concentration of cTn was above the
99<sup>th</sup> percentile of the reference value.<sup><xref rid="r10" ref-type="bibr">10</xref></sup> Notwithstanding, the diagnosis of myocardial
infarction was based on the updated criteria of the European Society of Cardiology,
the American College of Cardiology Foundation, the American Heart Association and
the World Heart Federation (ESC/ACCF/AQHA/WHF) document titled Third Universal
Definition of Myocardial Infarction.<sup><xref rid="r12" ref-type="bibr">12</xref></sup> This international expert consensus document establishes that
the preferred biomarker of necrosis is cTn and at least one of the five additional
criteria: ischemic symptoms; new significant ST/T wave changes or new LBBB; new
pathologic Q waves; imaging demonstration of new loss of viable myocardium (or new
regional wall motion abnormality); and intracoronary thrombus (identified by
angiography or autopsy). Following the same document, a periprocedural myocardial
infarction was considered when cTn elevation exceeded five times the 99<sup>th</sup>
percentile value of reference in patients with normal basaline values.</p><p>Patients who experienced some procedural complications, as coronary dissection,
longstanding periprocedural arrhythmias or cardiac arrest, were excluded from the
analysis. Thus, only cases with complete successful angioplasty and stenting, such
as cases in which all accessible and relevant lesions were treated, without
complications, with full intraluminal gain, and flow TIMI 3, were considered for the
analysis.</p><p>Kidney function was estimated measuring serum creatinine and glomerular filtration
rate (GFR) by means of the Cockcroft-Gault<sup><xref rid="r13" ref-type="bibr">13</xref></sup> creatinine clearance equation, before and after the PCI
procedure:</p><p>GFR= [(140 - age) x weight (kg)/(72 x serum creatinine (mg/dL)] x (0.85 in
women).</p><p>Patients were allocated in the five stages of chronic kidney disease (stages I-V),
according to their value of GFR (&#x0003c;15, 15-29, 30-59, 60-89 and &#x0003e;90 mL/min). GFR
was estimated before the intervention and 24 hours later.</p><p><underline>Statistical analysis</underline>. All values were expressed as mean
&#x000b1; standard deviation. Normal distribution of data was analyzed using the
Kolmogorov-Smirnov test, differences (before vs. after) in continuous variables were
evaluated using Student's paired <italic>t</italic> test, whereas unpaired
<italic>t</italic> test was used to evaluate intergroup differences and
percentage of change (deltas). Differences between categorical data, i.e.,
frequencies and percentages, were evaluated with z tests. A p value &#x0003c;0.05 was
considered as significant. Prism GraphPad(r) (GraphPad, San Diego, CA, USA) software
was used for statistical analysis.</p></sec><sec sec-type="results"><title>Results</title><p>All recruited patients completed the study protocol. <xref ref-type="table" rid="t1">Table 1</xref> gathers demographic and clinical baseline data. Both groups were
similar (i.e., no statistical difference was found, p = <italic>ns</italic>) in age,
gender distribution, occurrence of adiposity, hypertension and diabetes, previous
myocardial infarction and functional renal status. There were more patients in the
preconditioning group medicated with &#x003b2;-blockers (5 subjects) and statins (2
subjects, no significant differences), whereas more control patients were medicated
with insulin and metformin, in spite of the fact that the proportion of diabetes was
similar in both groups. Calcium channel blockers and renin-angiotensin axis
modulators were prescribed in similar proportion in both groups. Almost undetectable
quantities of cTn were found in all patients, and none had, before the intervention,
ST abnormalities.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic and clinical characteristics of patients</p></caption><table frame="hsides" rules="groups"><colgroup width="20%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="2" align="left" colspan="1"><bold>Variable</bold></th><th colspan="2" align="center" rowspan="1"><bold>ControlGroup (n=23)</bold></th><th colspan="2" align="center" rowspan="1"><bold>PreconditioningGroup
(n=23)</bold></th></tr><tr><th align="center" rowspan="1" colspan="1"><bold>x</bold></th><th align="center" rowspan="1" colspan="1"><bold>SD</bold></th><th align="center" rowspan="1" colspan="1"><bold>x</bold></th><th align="center" rowspan="1" colspan="1"><bold>SD</bold></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Age (years)</bold></td><td align="center" rowspan="1" colspan="1">66.1</td><td align="center" rowspan="1" colspan="1">11.3</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">6.9</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Body mass index (kg/m<sup>2</sup>)</bold></td><td align="center" rowspan="1" colspan="1">26.8</td><td align="center" rowspan="1" colspan="1">4.2</td><td align="center" rowspan="1" colspan="1">27.7</td><td align="center" rowspan="1" colspan="1">4.5</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">n</td><td align="center" rowspan="1" colspan="1">%</td><td align="center" rowspan="1" colspan="1">n</td><td align="center" rowspan="1" colspan="1">%</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Male</bold></td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">69</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Type 2 diabetes mellitus</bold></td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">79</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">60.8</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>High blood pressure</bold></td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">83</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">91.3</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Pharmacological treatment</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Aspirin</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">Clopidogrel</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003b2;-blockers</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">78</td></tr><tr><td align="left" rowspan="1" colspan="1">ACEI</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">56</td></tr><tr><td align="left" rowspan="1" colspan="1">ARBs</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">30.4</td></tr><tr><td align="left" rowspan="1" colspan="1">CCB</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">21.7</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">26</td></tr><tr><td align="left" rowspan="1" colspan="1">Statins</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">82.6</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">91.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Insulin</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">17.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Metformin</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">47.8</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Previous myocardial infarction</bold></td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">52</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ST elevation (0.5-1 mV)</bold></td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Baseline troponin I &#x0003c;0.04 ng/mL</bold></td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Glomerular filtration rate (mL/min/1.73
m<sup>2</sup>)</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c; 15 (renal failure, stage V)</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">15-29 (severe reduction of GFR, stage IV)</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">17.3</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">30-59 (moderate reduction of GFR, stage III)</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">17.3</td></tr><tr><td align="left" rowspan="1" colspan="1">60-89 (mild reduction of GFR, stage II)</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">30.4</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">43</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265; 90 (normal GFR, stage I)</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">26</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>SD: standard deviation; GFR: glomerular filtration rate; ACEI:
angiotensin-converting-enzyme inhibitors; ARBs: angiotensin II receptor
blockers; CCB: calcium-channels blockers.</p></fn></table-wrap-foot></table-wrap><p><underline>Angina pain during or after PCI</underline>. Only one patient in each
group experienced angina pain (grade 4 in both cases) during or immediately after
the angioplasty procedure.</p><p><underline>NO bioavailability</underline>. <xref ref-type="fig" rid="f1">Figure
1</xref> shows that the concentration of NOx in blood withdrawn from the
coronary artery to be stented, just in the proximity of the atherosclerotic lesion,
was significantly greater in preconditioned patients. This result points out that
preconditioning maneuver increased the availability of NO in the coronary artery
selected for stenting.</p><p><fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Local nitric oxide (NOx) corrected by creatinine levels in controls and
preconditioned patients. Data are expressed as means &#x000b1; SEM.</p></caption><graphic xlink:href="abc-107-02-0154-g01"/></fig></p><p><underline>Changes in cTn I</underline>. <xref ref-type="fig" rid="f2">Figure
2</xref> display changes in serum concentrations of cTn I at baseline and 24
hours in both study groups. Patients in the control group presented a small but
significant increase in cTn. Meanwhile, the marker remained unchanged in the
preconditioned group.</p><p><fig id="f2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Changes in serum concentrations of troponin-I at baseline and 24 hours
after percutaneous coronary intervention in control (left) and
preconditioning (right) groups. Data are expressed as means &#x000b1;
SEM.</p></caption><graphic xlink:href="abc-107-02-0154-g02"/></fig></p><p><underline>ECG changes</underline>. Four patients in the control and only one in the
preconditioning groups had ST elevation greater than 1mV 24 hours after PCI (a
non-significant statistical difference of 17.3% vs. 4.3%). <xref ref-type="fig" rid="f3">Figure 3</xref> shows the percentage of changes observed in the
summation of R waves in all 12 ECG leads, while <xref ref-type="fig" rid="f4">Figure
4</xref> exhibits those changes just in precordial leads.</p><p><fig id="f3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Percent changes in summation of R waves on all leads, from baseline to 24
hours after percutaneous coronary intervention (PCI) in control (left)
and preconditioning (right) groups</p></caption><graphic xlink:href="abc-107-02-0154-g03"/></fig></p><p><fig id="f4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Percent changes in summation of R waves on precordial leads, from
baseline to 24 hours after percutaneous coronary intervention (PCI) in
control (left) and preconditioning (right) groups.</p></caption><graphic xlink:href="abc-107-02-0154-g04"/></fig></p><p><xref ref-type="table" rid="t2">Table 2</xref> displays the effect of the PCI
procedure on R wave summation in control patients, as well as the effect of the
preconditioning maneuver on that variable.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>R wave summation in control and experimental groups</p></caption><table frame="hsides" rules="groups"><colgroup width="16%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th colspan="6" align="center" rowspan="1"><bold>Total R summation
(&#x003a3;)</bold></th></tr></thead><tbody><tr><td colspan="3" align="center" rowspan="1"><bold>Control Group, X&#x000b1;SD,
mm</bold></td><td colspan="3" align="center" rowspan="1"><bold>Preconditioning group, X&#x000b1;SD,
mm</bold></td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>&#x003a3;basal</bold></td><td align="center" rowspan="1" colspan="1"><bold>post PCI</bold></td><td align="center" rowspan="1" colspan="1"><bold>p value</bold></td><td align="center" rowspan="1" colspan="1"><bold> &#x003a3;basal</bold></td><td align="center" rowspan="1" colspan="1"><bold>post PCI</bold></td><td align="center" rowspan="1" colspan="1"><bold>p value</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">56.9&#x000b1;139</td><td align="center" rowspan="1" colspan="1">51.3&#x000b1;12.7</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.0001 </td><td align="center" rowspan="1" colspan="1">53.3&#x000b1;230</td><td align="center" rowspan="1" colspan="1">62.0&#x000b1;22.4</td><td align="center" rowspan="1" colspan="1">0.006</td></tr><tr style="border-bottom-style:solid;border-bottom-width:thin;border-top-style:solid;border-top-width:thin"><td colspan="6" align="center" rowspan="1"><bold>Precordial R wave
summation</bold></td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>&#x003a3;basal</bold></td><td align="center" rowspan="1" colspan="1"><bold>&#x003a3;post PCI</bold></td><td align="center" rowspan="1" colspan="1"><bold>p value</bold></td><td align="center" rowspan="1" colspan="1"><bold> &#x003a3;basal</bold></td><td align="center" rowspan="1" colspan="1"><bold>&#x003a3;post PCI</bold></td><td align="center" rowspan="1" colspan="1"><bold>p value</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">36.5&#x000b1;21.8</td><td align="center" rowspan="1" colspan="1">32&#x000b1;17.9</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">33.1&#x000b1;18</td><td align="center" rowspan="1" colspan="1">37.3&#x000b1;19.5</td><td align="center" rowspan="1" colspan="1">0.057</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>SD: standard deviation; PCI: percutaneous coronary interventions.</p></fn></table-wrap-foot></table-wrap><p>As a whole, it can be seen that PCI procedure had a clear-cut effect on the summation
of R waves, in all or only in precordial leads. In comparison, preconditioning
maneuver not only preserved but also enhanced the summation of R waves. All these
changes in the control and experimental groups reached statistical significance.</p><p><underline>Renal data</underline>. Contrast media injected did not differ between
groups (225.7 &#x000b1; 10.27 and 221.3 &#x000b1; 13.36 mL, for control and
preconditioning groups, respectively, p= 0.79). <xref ref-type="table" rid="t3">Table 3</xref> shows the effect of PCI on serum creatinine and GFR. In control
group, creatinine rose 0.11 mg/dL (+8.6%), while in the preconditioning group,
creatinine increased more, 0.17 mg/dL (+17%). Nevertheless, GFR descended 6
mL/min/1.73m<sup><xref rid="r2" ref-type="bibr">2</xref></sup> (-9.5%) in
control patients, whilst in preconditioning patients, it fell 6.7 (-10.6%). None of
those differences were statistically significant.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Serum creatinine and GFR values in control and experimental patients before
and after PCI</p></caption><table frame="hsides" rules="groups"><colgroup width="16%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th colspan="3" align="center" rowspan="1"><bold>Control</bold></th><th colspan="3" align="center" rowspan="1"><bold>Preconditioning</bold></th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><bold>Cr basal</bold></td><td align="center" rowspan="1" colspan="1"><bold>Cr post PCI</bold></td><td align="center" rowspan="1" colspan="1"><bold>p</bold></td><td align="center" rowspan="1" colspan="1"><bold>Cr basal</bold></td><td align="center" rowspan="1" colspan="1"><bold>Cr post PCI</bold></td><td align="center" rowspan="1" colspan="1"><bold>p</bold></td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>mg/dL</bold></td><td align="center" rowspan="1" colspan="1"><bold>mg/dL</bold></td><td align="center" rowspan="1" colspan="1"><bold>value</bold></td><td align="center" rowspan="1" colspan="1"><bold>mg/dL</bold></td><td align="center" rowspan="1" colspan="1"><bold>mg/dL</bold></td><td align="center" rowspan="1" colspan="1"><bold>value</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">1.28&#x000b1;0.63</td><td align="center" rowspan="1" colspan="1">1.39&#x000b1;0.67</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">1.0&#x000b1;0.32</td><td align="center" rowspan="1" colspan="1">1.17&#x000b1;0.36</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td colspan="2" align="center" rowspan="1">GFR mL/min/1.73 m<sup>2</sup></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td colspan="2" align="center" rowspan="1">GFR mL/min/1.73 m<sup>2</sup></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Basal</bold></td><td align="center" rowspan="1" colspan="1"><bold>Post-PCI</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1"><bold>Basal</bold></td><td align="center" rowspan="1" colspan="1"><bold>Post-PCI</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="center" rowspan="1" colspan="1">63&#x000b1;26.5</td><td align="center" rowspan="1" colspan="1">57&#x000b1;23.5</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">72.0&#x000b1;21.1</td><td align="center" rowspan="1" colspan="1">64.4&#x000b1;20.97</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>Cr: serum creatinine; GFR: glomerular filtration rate; PCI: percutaneous
coronary intervention. *No intergroup significant differences were
found.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>The main findings of this work showed that a RIPC induced an intracoronary increase
of NO levels resulting in a decrease in myocardial damage (measured as no increase
in cTn-I) with electrocardiographic increases in the summation of R waves,
suggesting an improved myocardium after elective PCI.</p><p>The mechanisms by which repeated episodes of ischemia-reperfusion in a non-cardiac
tissue or organ lead to subsequent myocardial protection against ischemia are not
completely understood. The effect of brief limb ischemia has been studied in both
animals and humans.<sup><xref rid="r5" ref-type="bibr">5</xref></sup> The work of
Loukogeorgais et al.<sup><xref rid="r14" ref-type="bibr">14</xref></sup>
demonstrated that limb occlusion in one arm diminishes endothelial dysfunction in
the contralateral arm. Several hypothetical mechanisms have been proposed to explain
this phenomenon, mainly the neural and humoral hypothesis. Remote tissue subject to
ischemia-reperfusion must produce one or several substances (adenosine, bradykinin,
calcitonin gene-related peptide, endogenous opioids, among others) that can
stimulate an efferent neural pathway with cardioprotective results or traversing the
blood stream can act directly in the endothelium of the coronary vessels, inducing a
preservation response (that is, reversing endothelial dysfunction).<sup><xref rid="r6" ref-type="bibr">6</xref></sup> Other proposed mechanism is the
activation of the enzymatic system of mitogen-activated protein kinases (MAPKs) p38,
Erk1/2 and JNK, in the remote tissue subjected to ischemia-reperfusion that can
exert positive modifications yielding to ischemic protection in the distant
myocardium.<sup><xref rid="r15" ref-type="bibr">15</xref></sup> More
recently, the role of NO has emerged as the pivotal mechanism explaining ischemia
protection, classical or remote. There is evidence about the induction by RIPC of
increased activation of endothelial NO synthase (eNOS), rather than increased
expression,<sup><xref rid="r16" ref-type="bibr">16</xref></sup> as well as
an increase of NO production and its oxidation products nitrites/nitrates. In
elegant experiments using the rat cremaster flap <italic>in vivo</italic> microscopy
model, K&#x000fc;ntscher et al. have demonstrated that NO caused higher capillary
flow and faster red blood cell velocity in arterioles and capillaries, while
L-nitroarginine methylesther (L-NAME), a direct inhibitor of NOS, inhibits the
preconditioning effect.<sup><xref rid="r17" ref-type="bibr">17</xref></sup> NO, the
signaling molecule iconic of endothelial function, exerts plentiful biological
actions that can explain its cardiovascular protection effects: modulation of
excitability, attenuation of cellular stress response, arteriolar and capillary
dilation, antioxidant, antiinflammatory, antifibrotic, antithrombotic and
antiapoptotic effects, among others. Besides, NO functions also as an intracellular
messenger, a paracrine molecule, a neurotransmitter, or even as a hormone with
different distant effects, generally beneficial.<sup><xref rid="r18" ref-type="bibr">18</xref></sup></p><p>Although our work demonstrated a clear increase in NO (indirectly measured through
its degradation products, NO<sub>2</sub>/NO<sub>3</sub>) levels in the vicinity of
coronary atherosclerotic plaque after remote preconditioning, just before
angioplasty intervention, the metabolic changes caused by the preconditioning
maneuver are not at all the only source of NO production. It is now known, for
example, that nitrite can be the source of NO mainly in ischemic or hypoxic
conditions, besides the classical NO synthase pathway.<sup><xref rid="r19" ref-type="bibr">19</xref></sup> Even though, the production of NO through the
preconditioning phenomenon is still an explanation of the myocardium salvage shown
in our study (comparatively lower levels of serum cTn, and preservation or gain of
electrocardiographic R waves after the coronary intervention), as the rescue was
seen in the preconditioned patients and not in the controls.</p><p>On this regard, the sensitivity of current necrosis biomarkers makes it possible to
detect minute myocardial necrosis, making apparently easier the diagnosis of this
clinical entity. However, the criteria for the diagnosis of myocardial infarction
and periprocedural myocardial infarction have been modified several times in the
last few years, introducing considerable confusion in the matter.<sup><xref rid="r19" ref-type="bibr">19</xref></sup> According to current concepts,
increases of necrosis markers above the 99<sup>th</sup> percentile of the reference
value are defined as myocardial necrosis ("myonecrosis"), while an increase of at
least five times above the reference value of the 99<sup>th</sup> percentile
supports the diagnosis of myocardial infarction.<sup><xref rid="r20" ref-type="bibr">20</xref></sup> This graded diagnostic differentiation is based on the fact
that a small increase in biomarkers can be seen in multiple conditions, such as
heart failure, myocarditis, myocardiopathy, renal insufficiency, pulmonary
thromboembolism, fast or slow arrhythmias, ventricular hypertrophy, cardiac toxicity
(v.gr., anthracyclines), heart surgery and trauma, anemia, shock and sepsis, among
many more.</p><p>The importance of periprocedural myocardial infarction or periprocedural myonecrosis
resides obviously in the amount of viable myocardial lost during coronary
manipulation, and, for this reason, it seems commonsensical prevent or at least
limit the occurrence of myocardial injury and its extension. Periprocedural
myocardial infarction is less clinically relevant than spontaneous myocardial
infarction, as it was shown in the ACUITY trial,<sup><xref rid="r21" ref-type="bibr">21</xref></sup> in which the former was associated with a mortality
relative risk of 7.49, whereas, in the latter, mortality did not increase.</p><p>Our study showed that in the control group a definite periprocedural myocardial loss
occurred. In those patients, mean cTn value increased seven times (0.1 to 0.7 ng/dL)
from baseline to post-intervention, meaning 17.5 times the 99<sup>th</sup>
percentile reference value of 0.04 ng/dL. While, at baseline, 11 patients had cTn
values greater than 0.04, in post-PCI that number increased to 19. In comparison, in
the experimental group, mean cTn values did not exceed the 99<sup>th</sup>
percentile reference value both at baseline and post-PCI (0.02 to 0.04 ng/dL). At
baseline, 8 patients had cTn values greater than 0.04, and after PCI only 9 showed a
high value. These results call attention to the salvage of myocardium during PCI
with the use of an easy to do, cheap and almost harmless preconditioning
maneuver.</p><p>Furthermore, the myocardial preservation effect of preconditioning was confirmed in
our study with ECG data. ECG is a time-honored diagnostic tool in the clinical
recognition of myocardial infarction, its topographic localization, estimation of
infarction size and prognosis. Several indexes and scoring electrocardiographic
systems were developed to reflect the functional state of the left ventricle in
times previous to image technologies apt to estimate very accurately systolic and
diastolic properties of the left ventricle. Unfortunately, the correlation among
several ECG scores and ejection fraction was rather poor.<sup><xref rid="r22" ref-type="bibr">22</xref></sup> More recently, in the era of coronary
intervention, the meaning of the evolution of R wave's voltages in different phases
of myocardial ischemia and reperfusion has attracted again more attention.<sup><xref rid="r23" ref-type="bibr">23</xref></sup> In the classical
electrophysiological explanation, electric activated myocardial cells generate
action potentials represented by vectors, whose frontal heads are positively
charged. Necrotic or extremely ischemic myocardial cells cannot generate these
electrical forces. Diverse clinical and experimental studies have shown that R wave
amplitude decreases notoriously during acute ischemia, but increases its voltage
during reperfusion.<sup><xref rid="r23" ref-type="bibr">23</xref>,<xref rid="r24" ref-type="bibr">24</xref></sup> This phenomenon probably indicates
that during an undetermined period of time myocardial cells attacked by ischemia are
not dead, but just in a critical <italic>pre-mortem</italic> state of extreme
injury, keeping only the basic supporting life systems. But if flow is
reestablished, these myocardial ischemic cells can restore fully its vitality and
functionality. It has been described that, in humans, undergoing coronary
angioplasty, during the brief episodes of ischemia caused by balloon inflation, R
wave amplitude increases significantly in almost all ECG leads. Although the real
cause of this voltage gain in the summation of R wave has not been convincingly
disclosed (maybe the result of left ventricular cavity expansion or conduction
alterations), anyhow this phenomenon is associated with acute ischemia, different
from the phenomenon observed in this work.<sup><xref rid="r25" ref-type="bibr">25</xref></sup> So, the amplitude variation of R waves represents this
"entrance and exit" of the cells in the ischemic dimly zone. Our data show that,
while in control patients myocardial loss occurred, in patients who underwent a
preconditioning maneuver, myocardium was better preserved.</p><p>On the other hand, our results showed that renal function was impaired in both
groups. The magnitude of the renal derangement was noticeable, but not prominent,
far away from the boundaries of the contrast-induced nephropathy (a 25% increase of
serum creatinine or 0.5 mg/dL absolute augment).<sup><xref rid="r26" ref-type="bibr">26</xref></sup> In our patients, the preconditioning maneuver had no
positive change in renal functionality.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>The easy to do, inexpensive and harmless arm cuff occlusion maneuver carried out
before PCI can protect from myocardial damage caused by coronary intervention itself
and post-angioplasty reperfusion lesion, due to greater NO bioavailability in the
atherosclerotic lesion.</p><sec><title>Study limitations</title><p>Even with a clear participation of NO in decreasing myocardial damage, the
complexity of preconditioning phenomena still needs more profound studies. For
example, that phenomenon is known to have two phases, an early one ("first
window"), beginning almost immediately and lasting several hours, and a delayed
one ("second window"), starting 12 to 24 hours later and with a longer duration
of 48-72 hours, termed the "Second Window of Protection" (SWOP) or late ischemic
preconditioning.<sup><xref rid="r6" ref-type="bibr">6</xref></sup> While
in the first "window" myocardial preconditioning provokes vasodilation, in the
second "window", various downregulation changes occurred in proteins and the
expression genes encoding several proteins related to oxidation, heat shock
protective response, and activation of NF-&#x003ba;B, among others. Several other
investigations point out that NO can act as a mediator of "second-window"
ischemic preconditioning<sup><xref rid="r27" ref-type="bibr">27</xref></sup>
over the opening of the end effector of late preconditioning, the mitochondrial
ATP-sensitive potassium (mitoK-ATP)<sup><xref rid="r28" ref-type="bibr">28</xref></sup> channel. In addition, it has to be proven that NO acts
in both windows of the preconditioning phenomenon, as well as which is the
isoenzyme responsible for its increase production (eNOS or iNOS).</p><p>Finally, the clinical and prognostic consequences of the myocardium salvage
resulting from the preconditioning maneuver have yet to be tested in the long
range.</p></sec></sec></body><back><fn-group><fn fn-type="con"><p><bold>Author contributions</bold></p><p>Conception and design of the research: Arroyo-Mart&#x000ed;nez EA, Meaney A,
Alcocer-Chauvet A, Ceballos G, Meaney E; Acquisition of data: Arroyo-Mart&#x000ed;nez
EA, Meaney A, Rivera-Capello JM, Gonz&#x000e1;lez-Coronado V, Castillo G, N&#x000e1;jera N;
Analysis and interpretation of the data: Meaney A, Guti&#x000e9;rrez-Salme&#x000e1;n G, Ceballos
G, Meaney E; Statistical analysis: Arroyo-Mart&#x000ed;nez EA, Meaney A,
Guti&#x000e9;rrez-Salme&#x000e1;n G, Gonz&#x000e1;lez-Coronado V, Castillo G, N&#x000e1;jera N, Meaney E;
Obtaining financing: Meaney A, Meaney E; Writing of the manuscript:
Arroyo-Mart&#x000ed;nez EA, Guti&#x000e9;rrez-Salme&#x000e1;n G, Alcocer-Chauvet A, Ceballos G, Meaney
E; Critical revision of the manuscript for intellectual content:
Guti&#x000e9;rrez-Salme&#x000e1;n G, Alcocer-Chauvet A, Ceballos G, Meaney E.</p></fn><fn fn-type="COI-statement"><p><bold>Potential Conflict of Interest</bold></p><p>No potential conflict of interest relevant to this article was reported.</p></fn><fn fn-type="other" id="fn1"><label>*</label><p>Drs. Meaney and Ceballos co-senior this paper</p></fn><fn fn-type="supported-by"><p><bold>Sources of Funding</bold></p><p>There were no external funding sources for this study.</p></fn><fn fn-type="other"><p><bold>Study Association</bold></p><p>This study is not associated with any thesis or dissertation work.</p></fn></fn-group><ref-list><title>References</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murry</surname><given-names>CE</given-names></name><name><surname>Jennings</surname><given-names>RB</given-names></name><name><surname>Reimer</surname><given-names>KA</given-names></name></person-group><article-title>Preconditioning with ischemia: a delay of lethal cell injury in
ischemic myocardium</article-title><source>Circulation</source><year>1986</year><volume>74</volume><issue>5</issue><fpage>1124</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">3769170</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name></person-group><article-title>Remote ischemic preconditioning: current knowledge, unresolved
questions, and future priorities</article-title><source>J Cardiovasc Pharmacol Ther</source><year>2011</year><volume>16</volume><issue>3-4</issue><fpage>255</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">21821525</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kloner a</surname><given-names>R</given-names></name></person-group><article-title>Clinical application of remote ischemic
preconditioning</article-title><source>Circulation</source><year>2009</year><volume>119</volume><issue>6</issue><fpage>776</fpage><lpage>778</lpage><pub-id pub-id-type="pmid">19221230</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landymore</surname><given-names>RW</given-names></name><name><surname>Bayes</surname><given-names>AJ</given-names></name><name><surname>Murphy</surname><given-names>JT</given-names></name><name><surname>Fris</surname><given-names>JH</given-names></name></person-group><article-title>Preconditioning prevents myocardial stunning after cardiac
transplantation</article-title><source>Ann Thorac Surg</source><year>1998</year><volume>66</volume><issue>6</issue><fpage>1953</fpage><lpage>1957</lpage><pub-id pub-id-type="pmid">9930475</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thielmann</surname><given-names>M</given-names></name><name><surname>Kottenberg</surname><given-names>E</given-names></name><name><surname>Kleinbongard</surname><given-names>P</given-names></name><name><surname>Wendt</surname><given-names>D</given-names></name></person-group><article-title>Cardioprotective and prognostic e&#x000f0;ects of remoteischaemic
preconditioning in patients</article-title><comment>nullErratum in Lancet. 2013;382(9896):940.</comment><source>Lancet</source><year>2013</year><volume>382</volume><issue>9892</issue><fpage>597</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">23953384</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausenloy</surname><given-names>DJ</given-names></name><name><surname>Yellon</surname><given-names>DM</given-names></name></person-group><article-title>Remote ischaemic preconditioning: underlying mechanisms and
clinical application</article-title><source>Cardiovasc Res</source><year>2008</year><volume>79</volume><issue>3</issue><fpage>377</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">18456674</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoole</surname><given-names>SP</given-names></name><name><surname>Heck</surname><given-names>PM</given-names></name><name><surname>Sharples</surname><given-names>L</given-names></name><name><surname>Khan</surname><given-names>SN</given-names></name><name><surname>Duehmke</surname><given-names>R</given-names></name><name><surname>Densem</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Cardiac remote ischemic preconditioning in coronary stenting
(CRISP Stent) study: a prospective, randomized control trial</article-title><source>Circulation</source><year>2009</year><volume>119</volume><issue>6</issue><fpage>820</fpage><lpage>827</lpage><pub-id pub-id-type="pmid">19188504</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>World Medical Association</collab></person-group><article-title>World Medical Association Declaration of Helsinki: Ethical
Principles for Medical Research Involving Human Subjects</article-title><source>JAMA</source><year>2013</year><volume>310</volume><issue>20</issue><fpage>2192</fpage><lpage>2194</lpage></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaneyfelt</surname><given-names>TM</given-names></name><name><surname>Centor</surname><given-names>RM</given-names></name></person-group><article-title>Reassessment of clinical practice guidelines: go gently into that
good night</article-title><source>JAMA</source><year>2009</year><volume>301</volume><issue>8</issue><fpage>868</fpage><lpage>869</lpage><pub-id pub-id-type="pmid">19244197</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daubert</surname><given-names>MA</given-names></name><name><surname>Jeremias</surname><given-names>A</given-names></name></person-group><article-title>The utility of troponin measurement to detect myocardial
infarction: review of the current findings</article-title><source>Vasc Health Risk Manag</source><year>2010</year><volume>6</volume><fpage>691</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">20859540</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="book"><source>ACSM's Guidelines for exercise testing and prescription:primary
care</source><year>2010</year><edition>8th ed</edition><publisher-loc>Philadelphia</publisher-loc><publisher-name>Wolters Kluwer</publisher-name></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaffe</surname><given-names>AS</given-names></name></person-group><article-title>Third universal definition of myocardial
infarction</article-title><source>Clin Biochem</source><year>2013</year><volume>46</volume><issue>1-2</issue><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">23127386</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cockcroft</surname><given-names>DW</given-names></name><name><surname>Gault</surname><given-names>MH</given-names></name></person-group><article-title>Prediction of creatinine clearance from serum
creatinine</article-title><source>Nephron</source><year>1976</year><volume>16</volume><issue>1</issue><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">1244564</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loukogeorgakis</surname><given-names>SP</given-names></name><name><surname>Panagiotidou</surname><given-names>AT</given-names></name><name><surname>Broadhead</surname><given-names>MW</given-names></name><name><surname>Donald</surname><given-names>A</given-names></name><name><surname>Deanfield</surname><given-names>JE</given-names></name><name><surname>MacAllister</surname><given-names>RJ</given-names></name></person-group><article-title>Remote ischemic preconditioning provides early and late
protection against endothelial ischemia-reperfusion injury in humans: role
of the autonomic nervous system</article-title><source>J Am Coll Cardiol</source><year>2005</year><volume>46</volume><issue>3</issue><fpage>450</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">16053957</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vassalli</surname><given-names>G</given-names></name><name><surname>Milano</surname><given-names>G</given-names></name><name><surname>Moccetti</surname><given-names>T</given-names></name></person-group><article-title>Role of mitogen-activated protein kinases in myocardial
ischemia-reperfusion injury during heart transplantation</article-title><source>J Transplant</source><year>2012</year><volume>2012</volume><fpage>928954</fpage><lpage>928954</lpage><pub-id pub-id-type="pmid">22530110</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu-Amara</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>SY</given-names></name><name><surname>Quaglia</surname><given-names>A</given-names></name><name><surname>Rowley</surname><given-names>P</given-names></name><name><surname>Fuller</surname><given-names>B</given-names></name><name><surname>Seifalian</surname><given-names>A</given-names></name><etal/></person-group><article-title>Role of endothelial nitric oxide synthase in remote ischemic
preconditioning of the mouse liver</article-title><source>Liver Transpl</source><year>2011</year><volume>17</volume><issue>5</issue><fpage>610</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">21506249</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000fc;ntscher</surname><given-names>MV</given-names></name><name><surname>Kastell</surname><given-names>T</given-names></name><name><surname>Altmann</surname><given-names>J</given-names></name><name><surname>Menke</surname><given-names>H</given-names></name><name><surname>Gebhard</surname><given-names>MM</given-names></name><name><surname>Germann</surname><given-names>G</given-names></name></person-group><article-title>Acute remote ischemic preconditioning II: the role of nitric
oxide</article-title><source>Microsurgery</source><year>2002</year><volume>22</volume><issue>6</issue><fpage>227</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">12375287</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murad</surname><given-names>F</given-names></name></person-group><article-title>Discovery of some of the biological effects of nitric oxide and
its role in cell signaling</article-title><source>Biosci Rep</source><year>2004</year><volume>24</volume><issue>4-5</issue><fpage>452</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">16134022</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundberg</surname><given-names>JO</given-names></name><name><surname>Weitzberg</surname><given-names>E</given-names></name><name><surname>Gladwin</surname><given-names>MT</given-names></name></person-group><article-title>The nitrate-nitrite-nitric oxide pathway in physiology and
therapeutics</article-title><source>Nat Rev Drug Discov</source><year>2008</year><volume>7</volume><issue>2</issue><fpage>156</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">18167491</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muschart</surname><given-names>X</given-names></name><name><surname>Slimani</surname><given-names>A</given-names></name><name><surname>Jamart</surname><given-names>J</given-names></name><name><surname>Chenu</surname><given-names>P</given-names></name><name><surname>Dangoisse</surname><given-names>V</given-names></name><name><surname>Gabriel</surname><given-names>L</given-names></name><etal/></person-group><article-title>The different mechanisms of periprocedural myocardial infarction
and their impact on in-hospital outcome</article-title><source>J Invasive Cardiol</source><year>2012</year><volume>24</volume><issue>12</issue><fpage>655</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">23220981</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moussa</surname><given-names>ID</given-names></name><name><surname>Klein</surname><given-names>LW</given-names></name><name><surname>Shah</surname><given-names>B</given-names></name><name><surname>Mehran</surname><given-names>R</given-names></name><name><surname>Mack</surname><given-names>MJ</given-names></name><name><surname>Brilakis</surname><given-names>ES</given-names></name><etal/></person-group><article-title>Consideration of a new definition of clinically relevant
myocardial infarction after coronary revascularization: an expert consensus
document from the society for cardiovascular angiography and interventions
(SCAI)</article-title><source>J Am Coll Cardiol</source><year>2013</year><volume>62</volume><issue>17</issue><fpage>1563</fpage><lpage>1570</lpage><pub-id pub-id-type="pmid">24135581</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Bertrand</surname><given-names>M</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Dangas</surname><given-names>G</given-names></name><name><surname>Farkouh</surname><given-names>ME</given-names></name><name><surname>Feit</surname><given-names>F</given-names></name><etal/></person-group><article-title>Acute Catheterization and Urgent Intervention Triage strategY
(ACUITY) trial: study design and rationale</article-title><source>Am Heart J</source><year>2004</year><volume>148</volume><issue>5</issue><fpage>764</fpage><lpage>775</lpage><pub-id pub-id-type="pmid">15523305</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>SG</given-names></name><name><surname>Abouantoun</surname><given-names>S</given-names></name><name><surname>Savvides</surname><given-names>M</given-names></name><name><surname>Madsen</surname><given-names>EB</given-names></name><name><surname>Froelicher</surname><given-names>V</given-names></name></person-group><article-title>Limitations of electrocardiographic scoring systems for
estimation of left ventricular function</article-title><source>J Am Coll Cardiol</source><year>1983</year><volume>1</volume><issue>6</issue><fpage>1479</fpage><lpage>1488</lpage><pub-id pub-id-type="pmid">6853900</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>P</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Decreases in electrocardiographic R-wave amplitude and QT
interval predict myocardial ischemic infarction in Rhesus monkeys with left
anterior descending artery ligation</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>8</issue><elocation-id/></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isobe</surname><given-names>S</given-names></name><name><surname>Takada</surname><given-names>Y</given-names></name><name><surname>Ando</surname><given-names>A</given-names></name><name><surname>Ohshima</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Nanasato</surname><given-names>M</given-names></name><etal/></person-group><article-title>Increase in electrocardiographic R-waves after revascularization
in patients with acute myocardial infarction</article-title><source>Circ J</source><year>2006</year><volume>70</volume><issue>11</issue><fpage>1385</fpage><lpage>1391</lpage><pub-id pub-id-type="pmid">17062958</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinno</surname><given-names>MC</given-names></name><name><surname>Kowalski</surname><given-names>M</given-names></name><name><surname>Kenigsberg</surname><given-names>DN</given-names></name><name><surname>Krishnan</surname><given-names>SC</given-names></name><name><surname>Khanal</surname><given-names>S</given-names></name></person-group><article-title>R-wave amplitude changes measured by electrocardiography during
early transmural ischemia</article-title><source>J Electrocardiol</source><year>2008</year><volume>41</volume><issue>5</issue><fpage>425</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">18353345</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gassanov</surname><given-names>N</given-names></name><name><surname>Nia</surname><given-names>AM</given-names></name><name><surname>Caglayan</surname><given-names>E</given-names></name><name><surname>Er</surname><given-names>F</given-names></name></person-group><article-title>Remote ischemic preconditioning and renoprotection: from myth to
a novel therapeutic option?</article-title><source>J Am Soc Nephrol</source><year>2014</year><volume>25</volume><issue>2</issue><fpage>216</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">24309187</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>N</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Ohler</surname><given-names>A</given-names></name><name><surname>O'Rourke</surname><given-names>B</given-names></name><name><surname>Marb&#x000e1;n</surname><given-names>E</given-names></name></person-group><article-title>Activation of mitochondrial ATP-dependent potassium channels by
nitric oxide</article-title><source>Circulation</source><year>2000</year><volume>101</volume><issue>4</issue><fpage>439</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">10653837</pub-id></element-citation></ref></ref-list></back></article>